zilovertamab vedotin + bendamustine + rituximab

This is a **combination regimen** consisting of **zilovertamab vedotin**, **bendamustine**, and **rituximab**. - **Zilovertamab vedotin** is an investigational antibody-drug conjugate (ADC) that targets **receptor tyrosine kinase-like orphan receptor 1 (ROR1)**, a protein expressed on certain hematologic malignancies. It consists of a monoclonal antibody targeting ROR1 linked to a cytotoxic agent (vedotin). - **Bendamustine** is a nitrogen mustard derivative with alkylating activity, used as a cytotoxic chemotherapy agent. - **Rituximab** is a monoclonal antibody that selectively binds to the CD20 antigen on B lymphocytes, promoting cell death via multiple mechanisms including antibody-dependent cellular cytotoxicity and complement activation. This combination has not been specifically described in published pivotal studies as a regimen, but all three agents are individually and in combinations under clinical investigation for the treatment of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and indolent non-Hodgkin lymphoma. Zilovertamab vedotin + rituximab (with other agents, e.g., cyclophosphamide, doxorubicin, prednisone) is under phase 2/3 investigation. Bendamustine + rituximab is an established regimen for NHL and MCL[2][4][8].